Trade Report: The Medicines Co. (MDCO) Stock Rating Reaffirmed by Leerink Swann

The Medicines Co. (MDCO) Stock Rating Reaffirmed by Leerink Swann

Leerink Swann reaffirmed their outperform rating on shares of The Medicines Co. (NASDAQ:MDCO) in a report published on Saturday morning.

MDCO has been the subject of a number of other research reports. Cowen and Company reissued a buy rating and set a $45.00 price target on shares of The Medicines in a research report on Friday, August 5th. Jefferies Group reissued a buy rating and set a $43.00 price target on shares of The Medicines in a research report on Wednesday, August 31st. Guggenheim reissued a buy rating and set a $55.00 price target on shares of The Medicines in a research report on Monday, August 15th. Bank of America Corp. reissued a buy rating on shares of The Medicines in a research report on Tuesday, July 12th. Finally, Zacks Investment Research raised shares of The Medicines from a sell rating to a hold rating in a research report on Tuesday, July 12th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The Medicines currently has an average rating of Buy and a consensus target price of $47.33.

The Medicines (NASDAQ:MDCO) opened at 35.41 on Friday. The firm’s market capitalization is $2.47 billion. The Medicines has a 1-year low of $27.50 and a 1-year high of $43.00. The stock’s 50 day moving average is $38.65 and its 200-day moving average is $36.24.

The Medicines (NASDAQ:MDCO) last released its quarterly earnings results on Wednesday, July 27th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.54. The Medicines had a negative net margin of 90.33% and a negative return on equity of 34.20%. The business earned $54.70 million during the quarter, compared to the consensus estimate of $41.93 million. During the same quarter last year, the company earned ($0.65) earnings per share. The business’s quarterly revenue was down 26.5% compared to the same quarter last year. Equities research analysts forecast that The Medicines will post ($1.36) EPS for the current year.

In other The Medicines news, Director Hiroaki Shigeta sold 3,849 shares of the firm’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $38.50, for a total value of $148,186.50. Following the sale, the director now directly owns 23,547 shares in the company, valued at $906,559.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Clive Meanwell sold 8,623 shares of the firm’s stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $40.00, for a total value of $344,920.00. Following the completion of the sale, the chief executive officer now owns 347,791 shares in the company, valued at $13,911,640. The disclosure for this sale can be found here. 7.90% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC bought a new stake in The Medicines during the second quarter worth about $100,000. BlackRock Inc. boosted its stake in The Medicines by 28.3% in the first quarter. BlackRock Inc. now owns 4,554 shares of the company’s stock worth $145,000 after buying an additional 1,005 shares during the last quarter. Strs Ohio boosted its stake in The Medicines by 22.4% in the second quarter. Strs Ohio now owns 6,000 shares of the company’s stock worth $201,000 after buying an additional 1,100 shares during the last quarter. HBK Investments L P bought a new stake in The Medicines during the first quarter worth about $210,000. Finally, Emerald Acquisition Ltd. bought a new stake in The Medicines during the second quarter worth about $258,000.

The Medicines Company Profile

Related posts

Leave a Comment